Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Immunomodulatory effects of mesenchymal stromal cell secretome accelerate repair in a sickle cell disease wound model.

Silveira BM., Ribeiro TO., Freire SM., Costa B., Maffili VV., Gonçalves MS.

Animal Study on Chronic Wound, Immune Modulation, published in Cell Immunol (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Cell Immunol (2025)
Country
Netherlands
Reported sample size
—
Source database
PubMed
PMID
41202405
DOI
10.1016/j.cellimm.2025.105047

Abstract (original English)

Chronic leg ulcers (CLUs) are a debilitating complication of sickle cell disease (SCD), driven by persistent inflammation, immune dysregulation, and vascular dysfunction. Current therapies fail to correct the hostile immune microenvironment that impairs repair. Here, we investigated the therapeutic potential of the adipose-derived mesenchymal stromal cell (ASC) secretome as a cell-free immunomodulatory approach in a preclinical SCD wound model. Full-thickness excisional wounds were induced in Townes HbSS mice and treated topically with ASC secretome or vehicle control. Treatment accelerated wound closure, enhanced re-epithelialization, and reduced inflammatory infiltrates. Histology revealed advanced collagen deposition and matrix organization, while immunofluorescence demonstrated increased CD31, α-SMA, and SM22 expression, indicating neovascularization and perivascular maturation. Gene expression profiling showed early upregulation of IL-10, TGF-β, and ARG1 and later downregulation of TNF, IL-1β, and NOS2, reflecting a shift toward a reparative immune milieu. Increased F4/80 + macrophages together with elevated CD31 + vascular markers were consistent with immune-vascular interactions. Collectively, these findings demonstrate that ASC secretome restores immune balance, supports vascular integrity, and promotes tissue regeneration in SCD-associated chronic wounds. This study pr

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsAnemia, Sickle CellMesenchymal Stem CellsWound HealingMiceDisease Models, AnimalSecretomeImmunomodulationMacrophagesMale

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research